Gary A. Lyons

Gary A. Lyons was named Rigel's Chairman of the Board in November 2014, having joined us as a director in October 2005. Mr. Lyons also serves as a member of the board of directors of Neurocrine Biosciences, Inc., where he served as Chief Executive Officer from 1993 until 2008. In addition, Mr. Lyons serves on the boards of directors of Novus Therapeutics, Inc., and Vical, Inc., and is Chairman of the board of directors at Retrophin, Inc. He served on the board of directors of PDL BioPharma, Inc., from July 2008 until he resigned on December 2008 to join the board of directors of Facet Biotech Corporation, following Facet's spin-off from PDL, and served on the board of directors there until Facet's acquisition of Abbott Laboratories in 2010. Mr. Lyons also served on the boards of directors of Cytori Therapeutics, Inc., NeurogesX, Inc. and KaloBios Pharmaceuticals, Inc. From 1983 to 1993, he held a number of senior management positions at Genentech, including Vice President of Business Development and Vice President of Sales, and also served as a member of Genentech's Executive Committee. Mr. Lyons was responsible for international licensing, acquisitions and partnering for Genentech's Corporate Venture Program and had operating responsibility for Genentech's two subsidiaries, Genentech Canada, Inc. and Genentech Limited (Japan). He holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management.